Kornimate/medical-research-clean huggingface dataset:
rtms and retraining in focal hand dystonia

Conditions: Focal Dystonia

Summary: this study is exploring a new experimental procedure in dystonia called repetitive transcranial magnetic brain stimulation (tms) combined with rehabilitation. the purpose of the study is to determine whether repetitive tms is effective as a treatment to reduce symptoms in dystonia as demonstrated by improved motor performance.

background: though the etiology of focal hand dystonia (fhd) is uncertain, two primary factors implicated in the development of dystonic symptoms are excessive cortical excitability and impaired sensorimotor processing. objective: the purpose of this study was to determine the functional efficacy and neural effects of a dual intervention of rtms and sensorimotor retraining. our working hypothesis is: subjects receiving the combined intervention will (1) display significantly improved handwriting measures; (2) report significant improvement in daily functional ability; (3) display reduced hand cramping compared; and (4) demonstrate reduced corticospinal excitability after the dual intervention when compared to the rtms+ stretching and massage (sham) intervention. methods: a randomized, single-subject, multiple baseline design with crossover is used for this study that will examine ten subjects with fhd with two interventions: five days of low-frequency 1 hz rtms + sensorimotor retraining (dual intervention) vs. rtms + stretching and massage (sham). the rtms is applied to the premotor cortex at 1 hz at 90% resting motor threshold for 1200 pulses. for sensorimotor retraining, a subset of the learning-based sensorimotor training program was followed.

Eligibility criteria:
inclusion criteria: * greater than 18 years of age * symptoms of focal hand dystonia or writer's cramp exclusion criteria: * history of seizure or other neurologic disorder

Keywords: focal hand dystonia (fhd) repetitive transcranial magnetic stimulation (rtms) sensorimotor retraining
open-label placebo for functional dyspepsia

Conditions: Dyspepsia

Summary: the study is evaluating the efficacy of open-label placebo for the treatment of functional dyspepsia.


Eligibility criteria:
inclusion criteria: * functional dyspepsia exclusion criteria: -
safety, tolerability, and immunogenicity of v114 compared to prevnar 13™ in ppsv23-vaccinated healthy adults ≥65 years of age (v114-007)

Conditions: Pneumococcal Infections

Summary: this study is designed to assess the safety, tolerability, and immunogenicity of v114 compared with prevnar 13™ in healthy adults 65 years of age or older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.


Eligibility criteria:
inclusion criteria: * is in good health (any underlying chronic illness must be documented to be in stable condition) * has documented proof of receipt of 23-valent pneumococcal polysaccharide vaccine ≥1 year prior to study entry * is a male or postmenopausal female exclusion criteria: * has received prior administration of any pneumococcal vaccine other than 23-valent pneumococcal polysaccharide vaccine * has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease * has a known hypersensitivity to any component of the pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine * is known or suspected impairment of immune function * has received systemic corticosteroids for \>=14 consecutive days and has not completed treatment \<=30 days prior to study entry, or received systemic corticosteroids exceeding physiologic replacement doses within 14 days prior to study vaccination * has a coagulation disorder contraindicating intramuscular vaccination * receives immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation, or autoimmune disease * has received a blood transfusion or blood products, including immunoglobulins within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. autologous blood transfusions are not considered an exclusion criterion * has participated in another clinical study of an investigational product within 2 months before the beginning of or any time during the duration of the current clinical study * is a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence.
stimulation of parents' self-efficacy beliefs and emotion coaching practices (h2m1)

Conditions: Behavior Problem

Summary: this research compared the efficacy of two parenting interventions that vary according to the number and the nature of variables in reducing preschoolers' externalizing behavior (eb). the goal was to identify which parenting intervention format (one-variable versus two-variable) caused higher behavioral adjustment in children.

the first format was a one-variable intervention manipulating parental self-efficacy beliefs. the second format was a two-variable intervention manipulating both parents' self-efficacy beliefs and emotion coaching practices. the two interventions shared exactly the same design, consisting of eight parent group sessions. effect on children's eb and observed behaviors were evaluated through a multi-method assessment at three points (pre-test, post-test and follow-up).

Eligibility criteria:
inclusion criteria: * children in the clinical or borderline range of the eb scale (cut-off = 21 or higher) of the child behavior checklist preschool form (achenbach \& rescorla, 2000a) * three to six years old and still in kindergarten at the beginning of the intervention exclusion criteria: * children with intellectual disabilities (average iq \< 5.5) * highly gifted children (average iq \>14.5)

Keywords: parenting intervention externalizing behavior emotion coaching practices self-efficacy beliefs
oral gabapentin and median nerve mobilization in the treatment of carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the present randomized clinical trial will perform a comparison of the pain reduction effects produced by the application of a non invasive and non pharmacological median nerve neural mobilization (physiotherapy treatment), to those effects produced by gabapentin and the absence of treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.

the present randomized clinical trial will perform a comparison of the pain reduction effects produced by the application of a non invasive and non pharmacological median nerve neural mobilization (physiotherapy treatment), to those effects produced by gabapentin and the absence of treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome. additionally, effects over the functionality of the affected upper limb will be evaluated and compared. subjects will be invited to participate and randomly allocated to 3 different groups.

Eligibility criteria:
inclusion criteria: * participants must be medically diagnosed with unilateral carpal tunnel syndrome (with confirmative electrodiagnostic findings). * full understanding of written and spoken spanish (language). * participants must freely consent to participate. * the presence of positive phalen an tinel sings. * the presence of carpal tunnel syndrome signs and symptoms exclusion criteria: * the lack to meet inclusion criterions, the presence of cognitive impairment, tumors, cancer, recent (affected) upper limb surgery or trauma, pregnancy, , deformities of the (affected) upper limb, recent skin injuries or infections (in the affected upper limb), autoimmune inflammatory conditions or flu type symptoms, allergy to gabapentin, and also: participants must not be (during the present investigation) under any type of pain reducing treatment (conservative, homeopathic, invasive or not invasive).

Keywords: gabapentin pain management physiotherapy
the effect of medical nutritional therapy on patients with sarcopenic obesity receiving peritoneal dialysis treatment

Conditions: Peritoneal Dialysis Complication; Sarcopenic Obesity

Summary: in this study, it was aimed to evaluate the effectiveness of medical nutrition therapy to be applied to patients with sarcopenic obesity receiving peritoneal dialysis treatment by measuring anthropometric measurements and blood parameters.

efficacy of medical nutrition therapy in patients with sarcopenic obesity receiving peritoneal dialysis treatment, general information form after patients filled in the voluntary consent form, sarc-f questionnaire as sarcopenia screening test, international physical activity questionnaire (ipaq), muscle mass, muscle strength, physical performance, bia measurement, anthropometric measurements, laboratory findings and three-day food consumption records will be evaluated.

Eligibility criteria:
inclusion criteria: * volunteering to participate in research * be between the ages of 18-70 * to receive peritoneal dialysis treatment and to come to the hospital regularly once a month for treatment exclusion criteria: * presence of any other disease that causes muscle wasting * patients using any supplement or enteral product in their diet
effectiveness and safety of tofacitinib in korean patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the objectives of this single center, prospective, non-interventional inception cohort is to understand patient characteristics, general treatment patterns, effectiveness, and safety of tofacitinib for rheumatoid arthritis patients in the real-world setting. 1. to evaluate the baseline characteristics of korean ra patients treated with tofacitinib 2. to evaluate the effectiveness and safety of tofacitinib in clinical practice in korean ra patients. 3. to further evaluate safety, effectiveness and demographic characteristics of the patients treated with tofacitinib matched with and compared to biologic dmards from the biopsy registry database.


Eligibility criteria:
inclusion criteria: a. patients who provide a written informed consent form of participating in this study. b. patients who are more than 19 years old. c. patients with moderately to severely active rheumatoid arthritis as defined per eular guidelines, who have had an inadequate response or are intolerant to methotrexate. exclusion criteria: a. patients who do not provide a written informed consent form of participating in this study
acqmap objectively visualize the etiology of recurrent af following a failed af ablation

Conditions: Recurrent Atrial Fibrillation

Summary: a prospective, single-arm, multi-center, multi-national, non-randomized, post-market study designed to provide clinical data regarding the use of the acqmap high resolution imaging and mapping system during an atrial fibrillation retreatment ablation procedure. (clp-af-004 \[eu\]) a prospective, single-arm, multi-center, non-randomized, pre-market study designed to provide clinical data regarding the use of the acqmap high resolution imaging and mapping system during an atrial fibrillation retreatment ablation procedure. (clp-af-005 \[canada\])

a prospective, single-arm, multi-center, multi-national, non-randomized, post-market study designed to provide clinical data regarding the use of the acqmap high resolution imaging and mapping system during an atrial fibrillation retreatment ablation procedure. the patient population includes men and women, eighteen (18) years of age or older. the treatment plan must include evaluation and ablation (as indicated) of pulmonary vein reconnections plus acqmap guided non-pv substrate ablation. subject assessments will occur at screening, procedure, hospital discharge, 3-, 6-, and 12-months. (clp-af-004 \[eu\]) a prospective, single-arm, multi-center, multi-national, non-randomized, pre-market study designed to provide clinical data regarding the use of the acqmap high resolution imaging and mapping system during an atrial fibrillation retreatment ablation procedure. the patient population includes men and women, eighteen (18) years of age or older. the treatment plan must include evaluation and ablation (as indicated) of pulmonary vein reconnections plus acqmap guided non-pv substrate ablation. subject assessments will occur at screening, procedure, hospital discharge, 3-, 6-, and 12-months. (clp-af-005 \[canada\])

Eligibility criteria:
inclusion criteria: * male or female eighteen (18) years of age or older * currently scheduled for a repeat endocardial ablation of af where the index atrial fibrillation ablation procedure was completed ≤ twenty-four (24) months prior to enrollment and the subject has demonstrated at least one episode of post-ablation non-self-terminating af exclusion criteria: * no more than two (2) previous left-atrial ablations * structural heart disease or implanted cardiac devices * history of blood clotting or bleeding disease * pregnant or lactating (current or anticipated during study follow up) * evidence of left atrial thrombus

Keywords: atrial fibrillation
julina post-marketing surveillance for climacteric symptoms in japan

Conditions: Osteoporosis, Postmenopausal

Summary: this study is a regulatory post-marketing surveillance in japan, and it is a local prospective and observational study of patients who have received julina for postmenopausal osteoporosis. the objective of this study is to assess safety and efficacy of using julina in clinical practice. a total 100 patients will be recruited and followed 3 years since starting julina administration.


Eligibility criteria:
inclusion criteria: * patients who received julina for postmenopausal osteoporosis exclusion criteria: * patients who are contraindicated based on the product label

Keywords: julina postmenopausal osteoporosis
association between labor induction and birth weight in cases of fetal macrosomia: the macromoda cohort study

Conditions: Birth Weight; Macrosomia, Fetal

Summary: the rising prevalence fof fetal macrosomia represents a significant challenge in obstetrics, affecting both maternal and neonatal outcomes. such challenges include complications like perineal tears and postpartum hemorrhage. concurrently, the frequency of labor induction practices on the rise, yet the implications for neonatal weight are inadequately understood. to address this gap, our study aims to evaluate the association between labor induction and neontal birth weight through a population-based cohort study. the findings have the potential to inform more accurate clinical guidelines, thereby enhancing the quality of maternity care.


Eligibility criteria:
inclusion criteria: * full-term deliveries (≥ 37 weeks of gestation) * singleton * birth weight \> 4000g * complete medical records available for analysis exclusion criteria: * delivery \< 37 weeks * uterus \> bi-scarred * presentation of the headquarters * maternal or fetal pathology modifying the route/time of delivery (pre-eclampsia, fetal heart rate abnormalities, cholestasis, chorioamnionitis, metrorrhagia, covering placenta, etc.)

Keywords: macrosomia labor induction perineal tears hemorrhage full-term deliveries singleton
evaluate safety and efficacy of an oral contraceptive (oc) preparation versus placebo for 6 treatment cycles in women with moderate acne

Conditions: Acne Vulgaris

Summary: the objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (drsp/ee) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles


Eligibility criteria:
inclusion criteria: * female age 14-45, with 10 to 100 comedones (noninflammatory lesions), 10 to 50 inflammatory lesions (papules or pustules), and not more than 35 nodules (\<5mm) on the face). exclusion criteria: * standard contraindications for use of combined oral contraceptives (class label)plus * subjects with acne and atopia, comedonal acne or acne conglobate, sandpaper acne or acne with multiple large nodes, cysts, fistular comedones, or abscessing fistular ducts * use of comedogenic covering cream, comedogenic sunscreens, other sex hormone preparations or any other anti-acne therapy (eg, light therapy, oleic acids, chemical peelings, mechanical extraction of comedones) * acne therapy with sex hormone preparations given over 3 months or longer and proved to be unsuccessful * preparations that have had an acne-inducing effect, eg, iodinated or bromated drugs, tuberculostatics, lithium, vitamin b1, b6, b12, d3, corticoids, acth, anabolics, quinine, disulfiram, methoxypsoralen, phenobarbital, phenytoin, trimethadione, thyroid depressants, and certain oily cosmetics

Keywords: moderate acne vulgaris acne
archival of human biological samples in cu-med biobank

Conditions: Healthy; Cancer; Heart Diseases; Neurological Diseases or Conditions; Kidney Diseases; Diabetes; Other Disease

Summary: cu-med biobank collaborates with different researchers for collecting and distributing human biospecimens and clinical data for assisting scientific research.

cu-med biobank will collect and store high-quality specimens from cancer-related or other diseases. all samples are linked to annotated clinical data from approved consented protocols. this system provides researchers with high- quality biological samples and comprehensive clinical, pathological including molecular/genetic information for their research. this standardized cu-med biobank is a pivotal bridge to improve the translation of basic research into clinical applications. these findings will contribute to improve prevention, enhance diagnosis, develop new treatment and eventual cure of diseases.

Eligibility criteria:
inclusion criteria: * enrolled subjects that have provided signed consent for the specimens and de-identified data to be collected, stored and distributed. exclusion criteria: * subjects without signed informed consent for the specimens and de-identified data to be collected, stored and distributed.

Keywords: biobanking
effect of non-surgical periodontal treatment on biomarker levels

Conditions: Healthy; Periodontitis

Summary: periodontitis is a destructive disease that follows untreated gingivitis and is characterized by gingival inflammation, clinical attachment loss, alveolar bone loss and periodontal pocket formation, increased tooth mobility and tooth loss. although the primary etiological factor is microbial dental plaque, the host response plays an important role in the transition from periodontal health to disease. smoking is a major risk factor for periodontitis and affects the formation and severity of the disease and healing after periodontal treatment by changing the host response to plaque. proinflammatory and antiinflammatory cytokines have an important role in the pathogenesis of periodontal disease. among these cytokines, interleukin (il)-1β, il-10 and currently il-39 have been associated with periodontal disease. further studies with post-treatment longitudinal evaluation are needed to elucidate the functions of il-39 and its possible role in the pathogenesis of periodontal diseases. in this study, it was aimed to investigate the effects of non-surgical periodontal treatment on salivary and gingival crevicular fluid (gcf) il-39, il-1β and il-10 levels in smokers and non-smokers with stage 3 grade b periodontitis and periodontally healthy individuals, both smokers and non-smokers. to the best of our knowledge, there is no study investigating the effects of non-surgical periodontal treatment and smoking on il-39. 50 individuals with periodontitis and 50 periodontally healthy individuals (total 100 individuals) will be included in our study, and these two groups will be divided into two sub-groups as smokers and non-smokers. clinical measurements (plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing), saliva and gcf samples will be taken from all individuals at the beginning of the study. non-surgical periodontal treatment will be performed in individuals with periodontitis. saliva and gcf samples will be collected before treatment. the clinical measurements, saliva and gcf collection will be repeated 12 weeks after the treatment. the saliva and gcf levels of il-39, il-1β and il-10 will be analyzed by elisa. cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. with this study, we aimed to develop il-39 diagnostic kits for the diagnosis of periodontal diseases, detection of disease activity, follow-up of response to treatment and healing.


Eligibility criteria:
inclusion criteria: * periodontal healthy group * stage iii grade b and c periodontitis group * to meet the above-mentioned periodontal health and disease criteria exclusion criteria: * chronic alcohol use, * oral contraceptive use, pregnancy, pregnant, * last 6 months antibiotic or anti-inflammatory drug use, * to have periodontal therapy in the last 6 months

Keywords: periodontal therapy biomarker periodontitis
cytokines and the risk of infection in liver cirrhosis

Conditions: Liver Cirrhosis

Summary: the aim of this study is to test whether the oscillation of cytokine concentrations in serum is able to predict the development of infection in patients with liver cirrhosis.

patients with liver cirrhosis frequently develop bacterial, viral or fungal infections which are the main trigger for decompensation of cirrhosis and development of complications and thereby infection hugely impacts morbidity and mortality in these patients. however, there is no clinical test available that allows rapid, on-site decision making if a patient is likely to develop an infection. the purpose of this study is to measure cytokines interleukin (il) 6, il8, il10 and tnfalpha in patients with liver cirrhosis over a long follow-up period and test whether these inflammatory markers are able to predict the occurrence of infection before it becomes clinically significant. for this purpose, one hundred fifty consecutive patients with diagnosis of liver cirrhosis will be followed bi-monthly for 18 months. blood samples will be collected for the cytokine measurements and infection cases will be reported at each study visit.

Eligibility criteria:
inclusion criteria: * patients with clinical, radiological and/or histological evidence of liver cirrhosis * age above 18 (inclusive) at the time of screening * able and willing to give written informed consent and to comply with the requirements of the study exclusion criteria: * infection during the last 14 days before screening * gastrointestinal bleeding within the last 14 days before screening * antibiotic therapy at the time of screening (except prophylaxis of spontaneous bacterial peritonitis) * shock or cardiac failure requiring inotrope treatment at the time of screening * hepatic encephalopathy grade \>2 * findings suggestive of organic nephropathy or a serum creatinine level of more than 2 mg/dl * human immunodeficiency virus infection at time of inclusion * use of immunomodulating agents within one month prior to screening (e.g. steroids) * any disease (e.g., advanced neoplasia) that could affect the short-term prognosis * any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject

Keywords: liver cirrhosis infection inflammation cytokines